These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29398430)

  • 1. Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy.
    Galema-Boers AM; Lenzen MJ; Engelkes SR; Sijbrands EJ; Roeters van Lennep JE
    J Clin Lipidol; 2018; 12(2):409-416. PubMed ID: 29398430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis.
    Schreuder MM; Hamkour S; Siegers KE; Holven KB; Johansen AK; van de Ree MA; Imholz B; Boersma E; Louters L; Bogsrud MP; Retterstøl K; Visseren FLJ; Roeters van Lennep JE; Koopal C
    Atherosclerosis; 2023 Nov; 384():117117. PubMed ID: 37080805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
    Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
    Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
    J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy.
    Miname MH; Bittencourt MS; Moraes SR; Alves RIM; Silva PRS; Jannes CE; Pereira AC; Krieger JE; Nasir K; Santos RD
    JACC Cardiovasc Imaging; 2019 Sep; 12(9):1797-1804. PubMed ID: 30448145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades.
    Elis A; Zhou R; Stein EA
    Am J Cardiol; 2011 Jul; 108(2):223-6. PubMed ID: 21545982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical determinants and treatment gaps in familial hypercholesterolemia: Data from a multi-ethnic regional health service.
    Zafrir B; Jubran A; Lavie G; Halon DA; Flugelman MY; Shapira C
    Eur J Prev Cardiol; 2017 May; 24(8):867-875. PubMed ID: 28186442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
    Vishwanath R; Hemphill LC
    J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Inertia in Patients With Familial Hypercholesterolemia.
    Langer A; Mancini GBJ; Tan M; Goodman SG; Ahooja V; Grégoire J; Lin PJ; Stone JA; Leiter LA
    J Am Heart Assoc; 2021 Jul; 10(14):e020126. PubMed ID: 34238023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia.
    Paquette M; Bernard S; Cariou B; Hegele RA; Genest J; Trinder M; Brunham LR; Béliard S; Baass A
    Arterioscler Thromb Vasc Biol; 2021 Oct; 41(10):2632-2640. PubMed ID: 34433300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of severe familial hypercholesterolemia in patients presenting for cardiac catheterization.
    Zafrir B; Shapira C; Lavie G; Halon DA; Flugelman MY
    J Clin Lipidol; 2016; 10(6):1338-1343. PubMed ID: 27919350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of cardiovascular risk factors in patients with familial hypercholesterolemia from the North-Eastern area of Romania.
    Vlad CE; Foia L; Florea L; Costache II; Covic A; Popescu R; Reurean-Pintilei D; Covic A
    Lipids Health Dis; 2021 Jan; 20(1):4. PubMed ID: 33430859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial hypercholesterolemia and cardiovascular disease in older individuals.
    Coutinho ER; Miname MH; Rocha VZ; Bittencourt MS; Jannes CE; Tada MT; Lima IR; Filho WS; Chacra AP; Pereira AC; Krieger JE; Santos RD
    Atherosclerosis; 2021 Feb; 318():32-37. PubMed ID: 33450476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
    deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
    Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
    Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials.
    Ridker PM; Amarenco P; Brunell R; Glynn RJ; Jukema JW; Kastelein JJ; Koenig W; Nissen S; Revkin J; Santos RD; Schwartz PF; Yunis C; Tardif JC;
    Am Heart J; 2016 Aug; 178():135-44. PubMed ID: 27502861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
    Kastelein JJ; Ginsberg HN; Langslet G; Hovingh GK; Ceska R; Dufour R; Blom D; Civeira F; Krempf M; Lorenzato C; Zhao J; Pordy R; Baccara-Dinet MT; Gipe DA; Geiger MJ; Farnier M
    Eur Heart J; 2015 Nov; 36(43):2996-3003. PubMed ID: 26330422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry.
    Saltijeral A; Pérez de Isla L; Alonso R; Muñiz O; Díaz-Díaz JL; Fuentes F; Mata N; de Andrés R; Díaz-Soto G; Pastor J; Pinilla JM; Zambón D; Pinto X; Badimón L; Mata P;
    Rev Esp Cardiol (Engl Ed); 2017 Jun; 70(6):444-450. PubMed ID: 27913073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Screening for familial hypercholesterolemia from low-density lipoprotein cholesterol levels at admission in the coronary care unit].
    Chemaly P; Nallet O; Delarche N; Legagneur C; Boulestreau R; Reibel I; Palette C; Grenier A; Courtade H; Beaune G; Belle L; Georges JL
    Ann Cardiol Angeiol (Paris); 2018 Nov; 67(5):300-309. PubMed ID: 30290906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.